F-18FDG

Phase 3Small molecule

NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

F-18FDG is one of 4 small molecule programs targeting PET. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PETRecruiting

PETPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in PET

#DrugCompanyPhaseTrials

F-Arag

CCellSight Technologies, Inc.

Phase 2

1 2

F-18FDG

NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Phase 3

1 3

XBD173

Novartis

Preclinical

1 4

Ziprazidone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalRecruiting

PET

NCT07087106

Clinical

Trials by Indication[1]

PET1 trial

Glucose Consumption in MS Using [F-18]FDG-PET

Recruiting·—·Phase 4·NCT07087106·50 enrolled

Normal Physiology1 trial

Reliability Of The Human Brain Connectome

Completed·NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 1·NCT02193425·112 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for F-18FDG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — F-18FDG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for F-18FDG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute on Alcohol Abuse and Alcoholism (NIAAA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

F-18FDG

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

PET1 trial

Normal Physiology1 trial

References

Drug Info

Quick Facts

Related News